文献速递胃肠外科肝胆胰外科围术期管理与 ERAS

氨甲环酸在普通外科中的安全性与有效性:POISE-3试验亚组分析

Safety and Efficacy of Tranexamic Acid in General Surgery.
PubMed 文献 · JAMA Surg · 2025-01-01

该研究为POISE-3随机对照试验的亚组分析,纳入3260例接受普通外科手术的心血管风险升高患者,比较预防性氨甲环酸(TXA)与安慰剂。

要点

  • 普通外科手术患者预防性使用TXA可显著降低围术期出血复合终点风险。
  • TXA不增加非心脏手术后心肌损伤、非出血性卒中、外周动脉血栓或症状性近端静脉血栓栓塞的复合风险。
  • 肝胰胆手术和结直肠手术亚组中TXA均降低出血复合终点。

核心结论

  • 在普通外科手术患者中,预防性TXA显著降低围术期出血风险,且不增加心血管风险。

研究设计与样本

  • POISE-3盲法、国际、多中心随机临床试验的亚组分析,比较TXA与安慰剂。
  • 共9535例患者随机,其中3260例接受普通外科手术;患者年龄≥45岁,接受非心脏手术,心血管风险升高,预期术后至少住院过夜。
  • 干预为手术开始和结束时预防性静脉给予1g TXA或安慰剂。

主要发现

  • 普通外科亚型中,肝胰胆手术(HR 0.55;95%CI 0.34-0.91;n=332)和结直肠手术(HR 0.67;95%CI 0.45-0.98;n=940)的出血复合终点降低。

临床怎么用

  • 对于心血管风险升高且接受普通外科手术(尤其是肝胰胆或结直肠手术)的患者,可考虑预防性使用TXA以减少围术期出血。
  • 使用TXA时需评估患者个体出血与血栓风险,本研究中TXA未增加主要心血管安全终点。

局限性

  • 本研究为预设亚组分析,结果需在更广泛普通外科人群中验证。
  • 原文未报告亚组分析的具体局限性描述。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Perioperative bleeding is common in general surgery. The POISE-3 (Perioperative Ischemic Evaluation-3) trial demonstrated efficacy of prophylactic tranexamic acid (TXA) compared with placebo in preventing major bleeding without increasing vascular outcomes in noncardiac surgery. OBJECTIVE: To determine the safety and efficacy of prophylactic TXA, specifically in general surgery. DESIGN, SETTING, AND PARTICIPANTS: Subgroup analyses were conducted that compared randomized treatment with TXA vs placebo according to whether patients underwent general surgery or nongeneral surgery in the POISE-3 blinded, international, multicenter randomized clinical trial. Participants were 45 years or older, were undergoing noncardiac surgery, had increased cardiovascular risk, and were expected to require at least an overnight hospital admission after surgery. Among 26 581 eligible patients identified, 17 046 were excluded, resulting in 9535 patients randomized to the POISE-3 trial. Participants were enrolled from June 2018 through July 2021. The data were analyzed during December 2023. INTERVENTION: Prophylactic, 1-g bolus of intravenous TXA or placebo at the start and end of surgery. MAIN OUTCOMES AND MEASURES: The primary efficacy outcome was a composite of life-threatening bleeding, major bleeding, or bleeding into a critical organ. The primary safety outcome was a composite of myocardial injury after noncardiac surgery, nonhemorrhagic stroke, peripheral arterial thrombosis, or symptomatic proximal venous thromboembolism at 30 days. Cox proportional hazards models were conducted, incorporating tests of interaction. RESULTS: Among 9535 POISE-3 participants, 3260 underwent a general surgery procedure. Mean age was 68.6 (SD, 9.6) years, 1740 were male (53.4%), and 1520 were female (46.6%). Among general surgery patients, 8.0% and 10.5% in the TXA and placebo groups, respectively, had the primary efficacy outcome (hazard ratio [HR], 0.74; 95% CI, 0.59-0.93; P = .01) and 11.9% and 12.5% in the TXA and placebo groups, respectively, had the primary safety outcome (HR, 0.95; 95% CI, 0.78-1.16; P = .63). There was no significant interaction by type of surgery (general surgery vs nongeneral surgery) on the primary efficacy (P for interaction = .81) and safety (P for interaction = .37) outcomes. Across subtypes of general surgery, TXA decreased the composite bleeding outcome in hepatopancreaticobiliary surgery (HR, 0.55; 95% CI, 0.34-0.91 [n = 332]) and colorectal surgery (HR, 0.67; 95% CI, 0.45-0.98 [n = 940]). There was no significant interaction across subtypes of general surgery (P for interaction = .68). CONCLUSIONS AND RELEVANCE: In this study, TXA significantly reduced the risk of perioperative bleeding without increasing cardiovascular risk in patients undergoing general surgery procedures. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03505723.

来源:JAMA Surg,查看原文。版权归原作者所有。

引用

  1. Park LJ, Marcucci M, Ofori SN, et al. Safety and Efficacy of Tranexamic Acid in General Surgery. JAMA Surg. 2025. PMID: 39813061. doi:10.1001/jamasurg.2024.6048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。